Want to see FBLG full AI Analyst Report?
FBLG Stock Chart & Stats
$1.53
-$0.09(-3.98%)
At close: 4:00 PM EST
$1.53
-$0.09(-3.98%)
Day’s Range― - ―
52-Week Range$0.73 - $14.66
Previous CloseN/A
Volume56.64K
Average Volume (3M)978.93K
Market Cap
$4.48M
Enterprise Value$2.43M
Total Cash (Recent Filing)$1.48M
Total Debt (Recent Filing)$2.48M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Jul 30, 2026EPS Estimate
-0.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.22
Shares Outstanding5,208,915
10 Day Avg. Volume1,423,641
30 Day Avg. Volume978,931
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.37
Enterprise Value/Ebitda-0.14
Forecast
1Y Price Target
$8.00Price Target Upside422.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.43
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Scientific LeadershipAdding Dr. Kathleen Rubins, a genomics scientist and experienced biomedical researcher, strengthens long-term scientific credibility and governance. Her expertise in molecular techniques and immune response can materially guide R&D prioritization, translational strategy, and external collaborations over months.
Listing Compliance And Market AccessDemonstrated compliance with Nasdaq listing criteria reduces immediate delisting risk and preserves public market access. This structural stability supports ongoing capital-raising options and investor visibility, improving the firm's ability to fund multi‑period R&D and maintain partnerships.
Operational Cost ReductionConsolidating facilities and cutting redundant rent by ~$0.8M is a durable improvement to the cost base. Lower recurring occupancy expense extends cash runway and allows reallocation to core lab operations, improving capital efficiency while the company advances its fibroblast pipeline.
Bears Say
No Revenue; Large Net LossesAbsence of commercial revenue and persistent, growing net losses (~$18.7M TTM) imply the business remains pre‑commercial with limited internal funding. Over months this sustains dependence on external capital and constrains reinvestment, slowing progress toward commercialization and scale.
Dilution Risk From FinancingsRecent at‑the‑market and private placement financings with warrants create material prospective dilution. Structurally, reliance on equity-linked instruments can compress existing ownership, influence governance dynamics, and reflect a recurring need to raise capital while product revenues remain absent.
Weakened Equity And Higher LeverageSharp decline in shareholders' equity paired with modest remaining debt raises leverage and reduces balance sheet cushion. Over a multi‑month horizon this limits financial flexibility, increases sensitivity to funding shocks, and may raise borrowing costs or restrict strategic options as R&D needs persist.
FibroBiologics, Inc. News
FBLG FAQ
What was FibroBiologics, Inc.’s price range in the past 12 months?
FibroBiologics, Inc. lowest stock price was $0.73 and its highest was $14.66 in the past 12 months.
What is FibroBiologics, Inc.’s market cap?
FibroBiologics, Inc.’s market cap is $4.48M.
When is FibroBiologics, Inc.’s upcoming earnings report date?
FibroBiologics, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 18 days.
How were FibroBiologics, Inc.’s earnings last quarter?
FibroBiologics, Inc. released its earnings results on Apr 30, 2026. The company reported -$1.31 earnings per share for the quarter, beating the consensus estimate of -$1.334 by $0.024.
Is FibroBiologics, Inc. overvalued?
According to Wall Street analysts FibroBiologics, Inc.’s price is currently Undervalued.
Does FibroBiologics, Inc. pay dividends?
FibroBiologics, Inc. does not currently pay dividends.
What is FibroBiologics, Inc.’s EPS estimate?
FibroBiologics, Inc.’s EPS estimate is -0.93.
How many shares outstanding does FibroBiologics, Inc. have?
FibroBiologics, Inc. has 5,208,915 shares outstanding.
What happened to FibroBiologics, Inc.’s price movement after its last earnings report?
FibroBiologics, Inc. reported an EPS of -$1.31 in its last earnings report, beating expectations of -$1.334. Following the earnings report the stock price went up 10.606%.
Which hedge fund is a major shareholder of FibroBiologics, Inc.?
Currently, no hedge funds are holding shares in FBLG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
FibroBiologics, Inc.
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
FBLG Stock 12 Month Forecast
Average Price Target
$8.00
▲(422.88% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Curis
―
Synlogic
―
Lexaria Bioscience
―
Processa Pharmaceuticals
―